Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aroa Biosurgery Ltd ( (AU:ARX) ) has provided an announcement.
Aroa Biosurgery Ltd has announced a change in the director’s interest notice, specifically involving John Diddams. The change includes the transfer of 100,000 fully paid ordinary shares from Galdarn Pty Ltd to Whitfield Investments Pty Ltd, with a total of 160,000 shares disposed of in an on-market sale valued at $77,474.96. This adjustment in shareholding reflects internal financial management and may impact the company’s stock distribution among stakeholders.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
More about Aroa Biosurgery Ltd
Aroa Biosurgery Ltd operates in the medical technology industry, focusing on the development and commercialization of regenerative tissue products. The company primarily offers products designed to improve healing in complex wounds and soft tissue reconstruction, catering to a global market with a focus on enhancing patient outcomes.
Average Trading Volume: 368,388
Technical Sentiment Signal: Sell
Current Market Cap: A$179.3M
For detailed information about ARX stock, go to TipRanks’ Stock Analysis page.